Stock Analiz

Halozyme Therapeutics, Inc. (HALO) earnings: date, estimates and history

Price $97.58 · data as of November 16, 2026

Next earnings report

Next reportNot announced yet
Quarterending December 31, 2026
EPS estimate$2.63
Revenue estimate$551M
Expected EPS growth+1197.5%

The date appears here once Halozyme Therapeutics confirms it, usually two to four weeks before the report.

Track record

Beat EPS estimates4 of 4
Average surprise+9.4%
Average move on report day±14.7%

Halozyme Therapeutics beat the consensus earnings estimate in 4 of its last 4 reports, by +9.4% on average. On report days the stock moved 14.7% on average, up or down.

Earnings history

ReportedEPS estimateEPS actualSurpriseRevenueRevenue growthStock move
November 5, 2026
Sep/2026
$2.36$2.39+1.5%$493M+39.2%−20.5%
August 6, 2026
Jun/2026
$1.82$2.28+25.5%$481M+47.7%+23.4%
May 11, 2026
Mar/2026
$1.52$1.60+5.3%$377M+42.2%+10.6%
November 3, 2025
Sep/2025
$1.63$1.72+5.5%$354M+22.1%+4.4%

EPS as compared with analyst estimates (adjusted EPS). Revenue growth is against the same quarter a year earlier. Stock move: change on the first trading day after the report.

Frequently asked questions

When is Halozyme Therapeutics’s next earnings date?

Halozyme Therapeutics has not confirmed its next report date yet. Its last report was on November 5, 2026.

Did Halozyme Therapeutics beat earnings last quarter?

Yes, it reported EPS of $2.39 on November 5, 2026 against an estimate of $2.36 (a +1.5% surprise), and the stock moved −20.5% the next trading day.

What EPS do analysts expect next quarter?

The consensus estimate is $2.63 per share on revenue of about $551M.

Report dates and estimates from analyst consensus data; results from company reports. Updated daily. Not investment advice. Earnings calendar